The FDA has approved two antibiotics, gepotidacin (Blujepa — GSK) and zoliflodacin (Nuzolvence — Entasis), for oral treatment of uncomplicated urogenital gonorrhea in patients ≥12 years old.1 Gepotidacin is approved for use in persons weighing ≥45 kg who have limited or no alternative treatment options; it was approved in 2025 for treatment of uncomplicated urinary tract infection in females.2 Zoliflodacin is approved for use in persons weighing ≥35 kg. Neither drug is indicated for treatment of rectal or pharyngeal gonorrhea.
- Drugs for Atopic Dermatitis
- In Brief: Extended Duration of Use for Nexplanon
- Addendum: Urinary Incontinence with Second-Generation Antipsychotic Drugs
- Comparison Chart: Topical Nonsteroidal Drugs for Atopic Dermatitis (online only)
- Comparison Chart: Interleukin (IL) Antagonists and Oral JAK Inhibitors for Moderate to Severe Atopic Dermatitis (online only)
ISSUE
The FDA has approved depemokimab (Exdensur – GSK), a long-acting interleukin-5 (IL-5) antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in patients ≥12 years old. Depemokimab is the fourth IL-5-directed treatment to be approved in the US for this indication; the IL-5 antagonists mepolizumab (Nucala) and reslizumab (Cinqair) and the IL-5 receptor alpha antagonist benralizumab (Fasenra) were approved earlier.1-3
MAINTENANCE TREATMENT — An inhaled corticosteroid (ICS) is the most effective maintenance treatment for asthma of any severity. Daily low-dose ICS treatment suppresses airway inflammation and reduces symptoms and exacerbations. Patients who remain symptomatic despite adherence to ICS monotherapy and good inhalation technique should receive maintenance treatment with a combination of an ICS and an …